Regular
NAV (25-Jul-24)
Returns (Since Inception)
Fund Size
₹986 Cr
Expense Ratio
2.28%
ISIN
INF789F01695
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
28 Jun 1999
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+46.90%
+45.90% (Cat Avg.)
3 Years
+14.22%
+14.66% (Cat Avg.)
5 Years
+26.18%
+26.30% (Cat Avg.)
10 Years
+13.62%
+16.02% (Cat Avg.)
Since Inception
+15.03%
— (Cat Avg.)
Equity | ₹970.99 Cr | 98.50% |
Debt | ₹1.25 Cr | 0.13% |
Others | ₹13.56 Cr | 1.38% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹111.82 Cr | 11.34% |
Cipla Ltd | Equity | ₹65.16 Cr | 6.61% |
Dr Reddy's Laboratories Ltd | Equity | ₹55.76 Cr | 5.66% |
Ajanta Pharma Ltd | Equity | ₹52.1 Cr | 5.29% |
Apollo Hospitals Enterprise Ltd | Equity | ₹40.08 Cr | 4.07% |
Procter & Gamble Health Ltd | Equity | ₹37.37 Cr | 3.79% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹35.43 Cr | 3.59% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹31.41 Cr | 3.19% |
Gland Pharma Ltd | Equity | ₹31.02 Cr | 3.15% |
Suven Pharmaceuticals Ltd | Equity | ₹31 Cr | 3.15% |
Torrent Pharmaceuticals Ltd | Equity | ₹30.93 Cr | 3.14% |
Aurobindo Pharma Ltd | Equity | ₹30.81 Cr | 3.13% |
Glenmark Pharmaceuticals Ltd | Equity | ₹30.8 Cr | 3.12% |
Fortis Healthcare Ltd | Equity | ₹30.16 Cr | 3.06% |
Zydus Lifesciences Ltd | Equity | ₹26.34 Cr | 2.67% |
Divi's Laboratories Ltd | Equity | ₹25.61 Cr | 2.60% |
Metropolis Healthcare Ltd | Equity | ₹24.73 Cr | 2.51% |
Alkem Laboratories Ltd | Equity | ₹21.23 Cr | 2.15% |
Pfizer Ltd | Equity | ₹20.12 Cr | 2.04% |
Jupiter Life Line Hospitals Ltd | Equity | ₹17.49 Cr | 1.77% |
Star Health and Allied Insurance Co Ltd | Equity | ₹16.03 Cr | 1.63% |
Syngene International Ltd | Equity | ₹15.13 Cr | 1.54% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹14.82 Cr | 1.50% |
Caplin Point Laboratories Ltd | Equity | ₹14.73 Cr | 1.49% |
Marksans Pharma Ltd | Equity | ₹14.28 Cr | 1.45% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹13.76 Cr | 1.40% |
Concord Biotech Ltd | Equity | ₹13.68 Cr | 1.39% |
Ipca Laboratories Ltd | Equity | ₹13.51 Cr | 1.37% |
Net Current Assets | Cash | ₹13.44 Cr | 1.36% |
Ami Organics Ltd | Equity | ₹13.34 Cr | 1.35% |
Alembic Pharmaceuticals Ltd | Equity | ₹13.15 Cr | 1.33% |
Windlas Biotech Ltd | Equity | ₹12.93 Cr | 1.31% |
Vijaya Diagnostic Centre Ltd | Equity | ₹11.23 Cr | 1.14% |
Poly Medicure Ltd | Equity | ₹11.11 Cr | 1.13% |
Indegene Ltd | Equity | ₹11.1 Cr | 1.13% |
Orchid Pharma Ltd | Equity | ₹10.09 Cr | 1.02% |
Sequent Scientific Ltd | Equity | ₹10.01 Cr | 1.02% |
Rainbow Childrens Medicare Ltd | Equity | ₹7.71 Cr | 0.78% |
Indoco Remedies Ltd | Equity | ₹5.02 Cr | 0.51% |
India (Republic of) | Bond - Short-term Government Bills | ₹1.25 Cr | 0.13% |
Clearing Corporation Of India Ltd. Std - Margin | Cash - Repurchase Agreement | ₹0.12 Cr | 0.01% |
Large Cap Stocks
33.41%
Mid Cap Stocks
28.60%
Small Cap Stocks
35.36%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹941.62 Cr | 95.52% |
Financial Services | ₹16.03 Cr | 1.63% |
Basic Materials | ₹13.34 Cr | 1.35% |
Standard Deviation
This fund
14.44%
Cat. avg.
14.65%
Lower the better
Sharpe Ratio
This fund
0.51
Cat. avg.
0.55
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Since May 2022
ISIN | INF789F01695 | Expense Ratio | 2.28% | Exit Load | 1.00% | Fund Size | ₹986 Cr | Age | 28 Jun 1999 | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Flat 15% tax on realised gains (STCG - short term capital gains)
10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)
Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹15.00 Cr | 46.7% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹713.42 Cr | 48.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹713.42 Cr | 46.3% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹29.73 Cr | 45.2% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹173.47 Cr | 45.0% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹173.47 Cr | 42.3% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2312.48 Cr | 45.8% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2312.48 Cr | 43.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹638.88 Cr | 47.4% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹17.23 Cr | 44.1% |
Total AUM
₹2,92,994 Cr
Address
UTI Towers, Gn Block, Mumbai, 400 051
Your principal amount will be at Very High Risk